Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
https://doi.org/10.21518/2079-701X-2014-10-52-55
Abstract
A definite progress has been achieved in the treatment of patients with multiple sclerosis so far. However, first-line MS disease-modifying medications (MSDMM) do not always contribute to the stabilization of the autoimmune process. Second-line medications, including natalizumab, are successfully used for aggressive, hard-to-treat forms of multiple sclerosis. Given the potential risks of opportunistic infection in natalizumab therapy, a risk stratification scheme for progressive multifocal encephalopathy (PME) was developed. Strict adherence to the algorithm of MS treatment allows to minimize the risk of complications and successfully manage the hard-to-treat manifestations.
About the Authors
E. V. Popova
City Clinical Hospital №24, Department of Health, Moscow, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
A. N. Boyko
City Clinical Hospital №24, Department of Health, Moscow, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
M. V. Davydovskaya
City Clinical Hospital №24, Department of Health, Moscow, branch №1, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
O. V. Boyko
City Clinical Hospital №24, Department of Health, Moscow, branch №1, Moscow Multiple Sclerosis Center
Russian Federation
Russian Federation
N. V. Khachanova
City Clinical Hospital №24, Department of Health, Moscow, branch №1, Moscow Multiple Sclerosis Center; Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol, 2009, 8(3): 254-60.
2. Munschauer F, Giovannoni G, Lublin F et al. Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Presentation at WCTRIMS. Montreal, 2008.
3. O'Connor PW et al. Return of Disease Activity After Cessation of Natalizumab Therapy in Patients with Multiple Sclerosis, Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9-12, 2009.
4. Pucci E, Giuliani G, Solari A et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews, 2011 Oct 5 (10): CD007621.
5. Stuve O, Cravens PD, Frohman EM et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology, 2009, 72 (5): 396-401.
6. Sorensen PS, Bertolotto A, Edan G et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler, 2012, 18 (2): 143-152.
7. Sormani MP, Stefano N. Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy J Neurol., 2014, 82: 1-2.
Review
For citations:
Popova EV, Boyko AN, Davydovskaya MV, Boyko OV, Khachanova NV. Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC). Meditsinskiy sovet = Medical Council. 2014;(10):52-55. (In Russ.) https://doi.org/10.21518/2079-701X-2014-10-52-55
Views:
507
Email this article 